A phase 1/2 trial of ruxolitinib and erlotinib in patients with EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib

INTRODUCTION: Patients with EGFR-mutant lung cancers develop resistance to EGFR tyrosine kinase inhibitors. New treatments are needed to address resistance not mediated by EGFR T790M; pre-clinical evidence suggests that the JAK/STAT signaling pathway is important in acquired resistance to EGFR-direc...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Thorac Oncol
Main Authors: Yu, Helena A., Perez, Leslie, Chang, Qing, Gao, Sizhi P., Kris, Mark G., Riely, Gregory J., Bromberg, Jacqueline
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5552054/
https://ncbi.nlm.nih.gov/pubmed/27613527
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2016.08.140
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados